CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer

Malachi Griffith^{1-4,11}, Nicholas C Spies^{1,11}, Kilannin Krysiak^{1,4,11}, Joshua F McMichael¹, Adam C Coffman¹, Arpad M Danos¹, Benjamin J Ainscough¹⁻³, Cody A Ramirez¹, Damian T Rieke⁵, Lynzey Kujan¹, Erica K Barnell¹, Alex H Wagner^{1,2}, Zachary L Skidmore¹, Amber Wollam¹, Connor J Liu¹, Martin R Jones⁶, Rachel L Bilski¹, Robert Lesurf¹, Yan-Yang Feng¹, Nakul M Shah¹, Melika Bonakdar⁶, Lee Trani¹, Matthew Matlock¹, Avinash Ramu¹, Katie M Campbell¹, Gregory C Spies¹, Aaron P Graubert¹, Karthik Gangavarapu⁷, James M Eldred¹, David E Larson^{1,3}, Jason R Walker¹, Benjamin M Good⁷, Chunlei Wu⁷, Andrew I Su⁷, Rodrigo Dienstmann⁸, Adam A Margolin⁹, David Tamborero¹⁰, Nuria Lopez-Bigas¹⁰, Steven J M Jones⁶, Ron Bose⁴, David H Spencer^{1,4}, Lukas D Wartman^{1,2,4}, Richard K Wilson¹⁻⁴, Elaine R Mardis¹⁻⁴ & Obi L Griffith¹⁻⁴

CIViC is an expert-crowdsourced knowledgebase for Clinical Interpretation of Variants in Cancer describing the therapeutic, prognostic, diagnostic and predisposing relevance of inherited and somatic variants of all types. CIViC is committed to open-source code, open-access content, public application programming interfaces (APIs) and provenance of supporting evidence to allow for the transparent creation of current and accurate variant interpretations for use in cancer precision medicine.

Understanding of the genetic heterogeneity and mutational landscape underlying cancer

has seen incredible advances in recent years. This has accelerated the implementation of precision medicine strategies in which clinicians and researchers target specific molecular variants with treatments tailored to the individual and their disease¹. The biomedical literature describing such associations is large and growing rapidly. As a result, the interpretation of individual variants observed in patients has become a bottleneck in clinical sequencing workflows². Many cancer hospitals and research centers are engaged in separate efforts to interpret cancer-driving variants and genes in the context of clinical relevance. These efforts are largely occurring within independent ‘information silos’, producing interpretations that require constant updates, lack community consensus and involve intense manual input.

Estimates of the proportion of patients with cancer who would benefit from comprehensive molecular profiling vary substantially³, in part because of the lack of both a community consensus definition of actionability and a comprehensive catalog of specific clinical variant interpretations. Achieving the goals of precision medicine will require this informa-

tion to be centralized, freely accessible, openly debated and accurately interpreted for application in the clinic. Existing efforts to facilitate clinical interpretation of variants include the Gene Drug Knowledge Database⁴, the Database of Curated Mutations⁵, ClinVar⁶, ClinGen⁷, PharmGKB⁸, Cancer Driver Log⁹, My Cancer Genome¹⁰, Jax-Clinical Knowledgebase¹¹, the Personalized Cancer Therapy Knowledgebase, the Precision Medicine Knowledgebase, the Cancer Genome Interpreter, OncoKB and others (**Supplementary Table 1**). These resources often have barriers to widespread adoption, including some combination of (i) no public access to content, (ii) restrictive content licenses, (iii) no public API, (iv) no bulk data download capabilities and (v) no mechanism for rapid improvement of the content (see **Supplementary Table 1** for detailed feature comparison). To address these limitations, we present CIViC, an open-access, open-source knowledgebase for expert crowdsourcing of Clinical Interpretation of Variants in Cancer (<http://civcdb.org/>; **Fig. 1**).

The critical distinguishing features of the CIViC initiative, in comparison to several of

¹McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri, USA. ²Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA. ³Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA. ⁴Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. ⁵Charité Comprehensive Cancer Center, Charité Universitätsmedizin, Berlin, Germany. ⁶Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. ⁷Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California, USA. ⁸Oncology Data Science Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain. ⁹Computational Biology, Oregon Health and Science University, Portland, Oregon, USA. ¹⁰Institute for Research in Biomedicine, Barcelona Institute of Science and Technology, Barcelona, Spain. ¹¹These authors contributed equally to this work. Correspondence should be addressed to M.G. (mgriffith@wustl.edu) or O.L.G. (obigriffith@wustl.edu).

one of four evidence types indicating whether a variant is predictive of response to therapy, prognostic, diagnostic and/or predisposing for cancer. Evidence records are also assigned to an evidence level ranging from established clinical utility (level A) to inferential (level E) evidence (**Supplementary Figs. 3 and 4**). The quality of the underlying published evidence is rated from one to five stars. As evidence records accumulate for a single variant, they are in turn synthesized into a human-readable ‘variant summary’ of the variant’s overall significance in cancer. Variants can also be aggregated into ‘variant groups’ that share a clinical significance (for example, imatinib resistance). All variant types are supported (including

structural variants, RNA fusions and other expression events) as well as all variant origins (somatic mutation, germline mutation and germline polymorphism). Genomic coordinates, transcript identifiers and variant synonyms are determined by curators, reviewed by editors and stored in a standardized format (for example, HGVS) for each variant. Additional variant information is imported through the MyVariant.info annotation API¹², providing links to complementary resources and variant annotations such as ClinVar⁶, COSMIC¹³ and ExAC¹⁴. Each variant is associated with a single gene, and each gene view provides a curated 'gene summary' synthesizing all of the variants it contains. Additional gene information is imported through the MyGene.info annotation API¹², allowing users to focus curation effort on clinical impact and not repeat the efforts of other databases. Integration of public ontologies and databases, such as Disease Ontology¹⁵ and Sequence Ontology¹⁶, allows CIViC's data to be formally structured (Supplementary Fig. 5) and integrated with other resources. This structure provides both computationally accessible information and human-interpretable content with the flexibility to capture key details for the wide range of variants and experiment types being interpreted (refer to the Supplementary Note for implementation details).

CIViC currently contains 1,678 curated interpretations of clinical relevance for 713 variants affecting 283 genes (Supplementary Fig. 6). These interpretations were curated from 1,077 published studies by 58 CIViC curators. CIViC evidence records are supported by a wide range of evidence levels and trust ratings, currently biased toward somatic alterations and positive associations with treatment response (Supplementary Fig. 7). At least one evidence record has been created for 209 cancer subtypes and 291 drugs, with some bias toward lung, breast, hematologic, colorectal and skin cancers and associated

targeted therapies (Supplementary Fig. 8). Supporting publications for these interpretations come from a large number of journals, primarily over the last five years, and tend to provide just one or two evidence records each (Supplementary Fig. 9). From the public launch of CIViC in June 2015 to December 2016, external curators (not affiliated with Washington University) contributed 46.7% of the evidence statements within the knowledgebase (Supplementary Fig. 6b). Thus far, submissions, revisions, comments and expert reviews have produced 11,254 distinct curation actions. These numbers continue to grow. More than 16,000 users have accessed CIViC interpretations from academic, governmental and commercial institutions around the world (Supplementary Fig. 6c,d). Early adopters of CIViC include leaders in developing cancer genomics pipelines¹⁷, the UCSC Genome Browser¹⁸ and Agilent's Cartagenia Bench Lab NGS. Early curation and content partners include the Gene Drug Knowledgebase⁴ and the Personalized Oncogenomics Program¹⁹. The CIViC resource is freely accessible without login, and no fees or exclusive access will be introduced in the future. Both academic and commercial adoption is free and encouraged. The variant and gene summaries, with additional statistics summarizing the level of supporting evidence in CIViC, can be automatically incorporated into clinical reports using the CIViC API or bulk data releases (updated nightly, with stable monthly releases) (Fig. 1). The source code for the CIViC website and public API are released under an open-source license (the Massachusetts Institute of Technology or 'MIT' license), and all curated content within CIViC is released under an open-access license (the Creative Commons Public Domain Dedication or 'CC0' license). The unencumbered availability of the CIViC bulk data releases, lack of requirements to establish a licensing agreement, the well-documented public API, and use of a structured

data model and ontologies allow rapid adoption of CIViC in clinical workflows. As the user base grows, the number of experts with a vested interest in the content will increase, driving community engagement and increasing curation from external users.

A critical concern, as CIViC content expands, is the maintenance of high-quality data and the inherent tradeoff between data quality and rapid or automated updating. The curation workflow of CIViC (Supplementary Fig. 10) requires agreement between at least two independent contributors before acceptance of new evidence or revisions of existing content (Supplementary Figs. 11 and 12). At least one of these users must be an expert editor, and editors are barred from approving their own contributions. CIViC includes features such as typeahead suggestions (recommendations that appear as soon as you start to type), automatic warning of possible duplicates, detailed documentation in all entry forms, and input validation to encourage high-quality data entry. To facilitate team curation efforts (Supplementary Fig. 10), the CIViC interface also includes features such as subscriptions, notifications and mentions. Curators can also use an advanced search interface to generate and share complex queries of CIViC data that help guide curation effort and content consumption (Supplementary Fig. 13). Many of these features were inspired by the 'best practices' of active online collaborative research and software development platforms, including BioStars²⁰ and GitHub.

A major challenge to the success of CIViC is the scope and complexity of the knowledge that needs to be summarized, and the development of strategies to assess the completeness of the resource. The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) recently reported on the variability among nine laboratories in clinical interpretations of germline variants relevant to Mendelian

Box 1 CIViC principles

1. **Interdisciplinary.** An interdisciplinary approach is needed to combine the expertise of genome scientists, healthcare providers, patient advocates and others.
2. **Community consensus.** The interpretations of clinical actionability required to enable precision medicine should be freely available and openly discussed across a diverse community. To facilitate consensus building, the interface must support direct contribution from members of the community.
3. **Transparency.** Content should be created with transparency, kept current, be comprehensive, track provenance and acknowledge the efforts of its creators.
4. **Computationally accessible.** The interface should be both structured enough to allow computational data mining (via APIs) and agile enough to handle the product of openly debated human interpretation.
5. **Freely accessible.** Curated knowledge will remain free and can be accessed anonymously without login unless the user wishes to contribute to content. No fees will be introduced.
6. **Open license.** CIViC will encourage both academic and commercial engagement through flexible licensing. Access will not be restricted by exclusive licensing.

diseases²¹, a field where the ACMG–AMP have proposed detailed standards and guidelines for variant classification²². This report identified a low rate of interpretation agreement between laboratories (34% concordance). However, discussion and review of criteria were able to more than double this concordance, demonstrating the need for and success of open discourse in clinical variant interpretation²¹. Recently, the Somatic Working Group (WG) of the Clinical Genome Resource (ClinGen) has published a consensus set of minimal variant-level data (MVLD) to help standardize data elements needed for curation of the clinical utility of somatic cancer variants²³. At present, cancer variant interpretation efforts that nominally have the same goals show a remarkably low overlap in source publications cited for these interpretations (1.6–71.6%, but generally less than 25%; **Supplementary Table 2**). This suggests that no single effort has comprehensively identified or summarized even the most relevant literature in this area, further illustrating the high curation burden involved. Conversely, these small overlaps emphasize the importance of reducing duplication of effort moving forward, especially considering the vastness of the existing literature and its tremendous growth rate. In CIViC, curation efforts thus far have focused on variants relevant to cancer types of particular interest at our center (for example, acute myeloid leukemia, breast cancer and lung cancer; **Supplementary Fig. 8b**), on variants identified as high priority by early CIViC partners^{4,19} and on variants targeted by proof-of-principle precision medicine ‘basket’ clinical trials such as NCI-MATCH (also known as EAY131 or NCT02465060). Our ability to provide expertise in these areas is complemented by the expert knowledge of other groups and organizations, making CIViC a more comprehensive resource than would be possible with a ‘silos data’ approach. To this end, recruitment of external contributors and domain experts from multiple fields is a top priority. This is accomplished in part through planning of CIViC-sponsored events in the cancer research and treatment community. We also allow for different levels of external community involvement, including submission of suggested publications to a queue to guide others to generate new evidence records (**Supplementary Fig. 14**).

Additional challenges faced by CIViC include long-term sustainability of funding, ensuring broad clinical engagement and maintaining the enthusiasm for the crowdsourcing efforts. We are addressing each of these challenges by engagement with other resources, experts and funding agencies with track records of long-term maintenance of

informatics resources (see the **Supplementary Note** for further discussion). To facilitate such engagement and seek broad input and external guidance for our efforts, we have recently established a Variant Interpretation for Cancer Consortium (VICC) as part of the Global Alliance for Genomics Health (GA4GH). We have also established a panel of clinical domain experts to provide independent guidance on development of the resource and to assess the completeness and accuracy of our variant curation efforts.

CIViC is designed to address many of the challenges of cancer variant interpretation. To our knowledge, CIViC is the only variant interpretation effort currently capable of leveraging community experts and additionally has the most open model (open-access content, open-source code and an open API). We believe that this open strategy represents a sustainable model for achieving current, standardized and comprehensive interpretations of the clinical relevance of cancer variants. As the community of contributors grows, an increased incentive will emerge to help keep CIViC updated with cutting-edge clinical trial and US Food and Drug Administration (FDA) investigational new drug (IND) findings. As we have created a comprehensive and modern API, centers can rapidly integrate CIViC into automated clinical report generation for gene panel, exome, whole-genome and RNA sequencing of tumor samples. While there are many challenges faced by an effort such as this one, we hope that, with input from a critical mass of interested parties, these challenges can be largely overcome. We invite all researchers, healthcare providers and patient advocates engaged in clinical interpretation of variants to join the community at CIViC (<http://civicdb.org/>).

URLs. The Clinical Interpretation of Variants in Cancer resource described by this work is available at <http://www.civicdb.org/>. Personalized Cancer Therapy Knowledgebase, <https://pct.mdanderson.org/>; Precision Medicine Knowledgebase, <https://pmkb.weill.cornell.edu/>; Cancer Genome Interpreter, <https://www.cancergenomeinterpreter.org/>; OncoKB, <http://oncokb.org/>; GitHub, <https://github.com/>; GA4GH Variant Interpretation for Cancer Consortium (VICC), <http://ga4gh.org/#/vicc>; MIT license, <https://opensource.org/licenses/MIT>; CC0 license, <https://creativecommons.org/publicdomain/zero/1.0/>.

Note: Any Supplementary Information and Source Data files are available in the online version of the paper (doi:10.1038/ng.3774).

ACKNOWLEDGMENTS

First and foremost, we are grateful to the community of curators, editors, domain experts and users who make CIViC possible. CIViC is supported by the

National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award number U01CA209936 to O.L.G. (with M.G. and E.R.M. as co-principal investigators). This work was also supported by a grant to R.K.W. from the National Human Genome Research Institute (NHGRI) of the NIH under award number U54HG003079. D.T.R. was supported by the German Federal Ministry of Education and Research under award numbers 031L0030E and 031L0023B. The Institute for Research in Biomedicine is a recipient of a Severo Ocho Centre of Excellence Award from MINECO (Government of Spain) and is supported by CERCA (Generalitat de Catalunya). D.T. is funded by a grant from the Spanish Ministry of Economy and Competitiveness and FEDER/UE (SAF2015-74072-JIN). M.G. is supported by the NHGRI under award number K99HG007940. O.L.G. is supported by the NCI under award number K22CA188163. L.D.W. is supported by the NCI under award number K08CA166229. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

AUTHOR CONTRIBUTIONS

M.G., N.C.S., K.K. and O.L.G. wrote the paper with input from A.M.D., E.K.B., E.R.M., A.H.W., R.L., A.C.C., J.F.M., B.J.A., Z.L.S., C.A.R., C.J.L., D.T.R. and G.C.S. A.C.C. led the back-end code development with contributions from N.C.S., J.F.M., M.G., O.L.G., K.K., G.C.S. and K.G. J.F.M. led the front-end code development with contributions from A.P.G., A.C.C., K.K., M.G., O.L.G. and N.C.S. B.M.G., A.I.S., A.A.M., D.T., N.L.-B. and S.J.M.J. contributed ideas relating to crowdsourcing functionality and integration with existing community resources. J.M.E., D.E.L., C.W. and J.R.W. contributed software engineering expertise. Substantial curation efforts were contributed by M.G., N.C.S., K.K., A.M.D., B.J.A., C.A.R., D.T.R., L.K., E.K.B., A.H.W., Z.L.S., A.W., C.J.L., M.R.J., R.L.B., R.L., Y.-Y.F., N.M.S., M.B., L.T., M.M., A.R., K.M.C., R.D., R.B., D.H.S., L.D.W., E.R.M. and O.L.G. Guidance on developing CIViC for clinical applications was provided by R.D., R.B., D.H.S. and L.D.W. Trainee supervision and project leadership were provided by M.G., R.K.W., E.R.M. and O.L.G.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0)

licence. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons licence, users will need to obtain permission from the licence holder to reproduce the material. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>

- Collins, F.S. & Varmus, H. A new initiative on precision medicine. *N. Engl. J. Med.* **372**, 793–795 (2015).
- Good, B.M., Ainscough, B.J., McMichael, J.F., Su, A.I. & Griffith, O.L. Organizing knowledge to enable personalization of medicine in cancer. *Genome Biol.* **15**, 438 (2014).
- Meric-Bernstam, F. *et al.* Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. *J. Clin. Oncol.* **33**, 2753–2762 (2015).
- Dienstmann, R., Jang, I.S., Bot, B., Friend, S. & Guinney, J. Database of genomic biomarkers for cancer

- drugs and clinical targetability in solid tumors. *Cancer Discov.* **5**, 118–123 (2015).
5. Ainscough, B.J. *et al.* DoCM: a database of curated mutations in cancer. *Nat. Methods* **13**, 806–807 (2016).
 6. Landrum, M.J. *et al.* ClinVar: public archive of interpretations of clinically relevant variants. *Nucleic Acids Res.* **44** D1, D862–D868 (2016).
 7. Rehm, H.L. *et al.* ClinGen—the Clinical Genome Resource. *N. Engl. J. Med.* **372**, 2235–2242 (2015).
 8. Thorn, C.F., Klein, T.E. & Altman, R.B. PharmGKB: the Pharmacogenomics Knowledge Base. *Methods Mol. Biol.* **1015**, 311–320 (2013).
 9. Damodaran, S. *et al.* Cancer Driver Log (CanDL): catalog of potentially actionable cancer mutations. *J. Mol. Diagn.* **17**, 554–559 (2015).
 10. Yeh, P. *et al.* DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. *Clin. Cancer Res.* **19**, 1894–1901 (2013).
 11. Patterson, S.E. *et al.* The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. *Hum. Genomics* **10**, 4 (2016).
 12. Xin, J. *et al.* High-performance web services for querying gene and variant annotation. *Genome Biol.* **17**, 91 (2016).
 13. Forbes, S.A. *et al.* COSMIC: somatic cancer genetics at high-resolution. *Nucleic Acids Res.* **45**, D777–D783 (2017).
 14. Karczewski, K.J. *et al.* The ExAC browser: displaying reference data information from over 60 000 exomes. *Nucleic Acids Res.* **45**, D840–D845 (2017).
 15. Kibbe, W.A. *et al.* Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data. *Nucleic Acids Res.* **43**, D1071–D1078 (2015).
 16. Eilbeck, K. *et al.* The Sequence Ontology: a tool for the unification of genome annotations. *Genome Biol.* **6**, R44 (2005).
 17. Gagan, J. & Van Allen, E.M. Next-generation sequencing to guide cancer therapy. *Genome Med.* **7**, 80 (2015).
 18. Speir, M.L. *et al.* The UCSC Genome Browser database: 2016 update. *Nucleic Acids Res.* **44** D1, D717–D725 (2016).
 19. Laskin, J. *et al.* Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. *Cold Spring Harb. Mol. Case Stud.* **1**, a000570 (2015).
 20. Parnell, L.D. *et al.* BioStar: an online question & answer resource for the bioinformatics community. *PLOS Comput. Biol.* **7**, e1002216 (2011).
 21. Amendola, L.M. *et al.* Performance of ACMG-AMP Variant-Interpretation Guidelines among nine laboratories in the Clinical Sequencing Exploratory Research Consortium. *Am. J. Hum. Genet.* **98**, 1067–1076 (2016).
 22. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* **17**, 405–424 (2015).
 23. Ritter, D.I. *et al.* Somatic cancer variant curation and harmonization through consensus minimum variant level data. *Genome Med.* **8**, 117 (2016).